Sponsor:
AIDS Malignancy Consortium
Code:
NCT07662928
Conditions
Adult Burkitt Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Bone Marrow Aspiration
Bone Marrow Biopsy
Computed Tomography
Cyclophosphamide
Brief summary:
Conditions
Adult Burkitt Lymphoma
Study ID
NCT07662928
Start date
Sep 16, 2026
Status verified date
Oct, 2026
Completion date
Apr 30, 2033
Anticipated
Primary completion date
May 30, 2031
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
43 participants
Anticipated
Allocation
Randomized
Intervention Model
Sequential
Primary purpose
Treatment
Arms
experimental: Cohort 1 (epcoritamab, DA-EPOCH-R)
active comparator: Cohort 2 Arm I (DA-EPOCH-R)
experimental: Cohort 2 Arm II (epcoritamab, DA-EPOCH-R)
Interventions
Biospecimen Collection
Bone Marrow Aspiration
Bone Marrow Biopsy
Computed Tomography
Cyclophosphamide
Doxorubicin
Echocardiography Test
Epcoritamab
Etoposide
Magnetic Resonance Imaging
Multigated Acquisition Scan
Positron Emission Tomography
Prednisone
Rituximab
Vincristine
Primary outcome measure
Locations
Memorial Sloan Kettering Cancer Center
Recruiting
New York, New York, United States, 10021
Contacts
Sponsor
AIDS Malignancy Consortium
Last update posted
Nov 17, 2026
Last verified
Oct, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-18. This information was provided to ClinicalTrials.gov by AIDS Malignancy Consortium on 2026-11-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.